Postdoctoral Research Associate University of Connecticut Storrs, Connecticut
Peritoneal metastasis is common in patients with ovarian, gastric, pancreatic and colon cancers, yet face delivery challenges due to limited tumor blood supply. We have demonstrated the efficacy of radionuclide loaded Mesoporous Silica Nanoparticles (166Ho-MSNs) delivered intraperitoneally in peritoneal metastases. However, its immunomodulatory effects remain unexplored.
This presentation will focus on the efficacy and immunomodulatory properties of 166Ho-MSNs, alone or in combination with an Immune checkpoint inhibitor (anti-PD-L1) in treating metastatic peritoneal cancers. We will highlight on prolonged tumor-free survival in mice treated with the combination therapy, inhibition on subcutaneous tumor growth in the rechallenged mice and explore the underlying mechanism. Firstly, we will present in-vitro findings using 3D spheroids to show how radiotherapy triggers and immune response, followed by in-vivo results in mice. Overall, the presentation will emphasize the potential of combining radiotherapy with immunotherapy to prevent tumor recurrence and support its clinical translation.
Learning Objectives:
Understand the potential of mesoporous silica nanoparticles mediated radionuclide therapy in metastatic peritoneal cancers.
Understand the basics of immune response mediated by radiation and the mechanism behind it.
Understand potential of combining radiotherapy with immunotherapy
